Mehdi Mirsaeidi1, Mary Beth Allen2, Golnaz Ebrahimi1, Dean Schraufnagel1. 1. Section of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, IL, USA. 2. Department of Public Health Management and Information Sciences, University of Louisville, Louisville, KY, USA.
Abstract
BACKGROUND: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are available measuring the cost burden of mycobacterial diseases at the national level. The purpose of this study is to evaluate the cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM cases in the United States from 2001 through 2012. METHODS: This study is a retrospective, community-based cost analysis of hospitalized patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through 2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utilization Project (HCUP), US Department of Health and Human Services. The statistical significance of observed trends of NTM and TB national hospital costs was calculated using Poisson log-linear regression. RESULTS: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total associated cost of these discharges was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the study period, the national hospital costs of pulmonary NTM increased at a statistically significant rate in the US over each year (P = 0.001). However, no such increase was found for national hospital costs of pulmonary TB. CONCLUSIONS: The national hospital cost of NTM management is increasing. These results emphasize the importance of continued research in pulmonary NTM in order to improve current guidelines in prevention and treatment strategies.
BACKGROUND:Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are available measuring the cost burden of mycobacterial diseases at the national level. The purpose of this study is to evaluate the cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM cases in the United States from 2001 through 2012. METHODS: This study is a retrospective, community-based cost analysis of hospitalized patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through 2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utilization Project (HCUP), US Department of Health and Human Services. The statistical significance of observed trends of NTM and TB national hospital costs was calculated using Poisson log-linear regression. RESULTS: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total associated cost of these discharges was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the study period, the national hospital costs of pulmonary NTM increased at a statistically significant rate in the US over each year (P = 0.001). However, no such increase was found for national hospital costs of pulmonary TB. CONCLUSIONS: The national hospital cost of NTM management is increasing. These results emphasize the importance of continued research in pulmonary NTM in order to improve current guidelines in prevention and treatment strategies.
Authors: Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Joseph O Falkinham; Steven M Holland; D Rebecca Prevots Journal: Am J Respir Crit Care Med Date: 2012-07-05 Impact factor: 21.405
Authors: Mark N Lobato; Yong-Cheng Wang; Jose E Becerra; Patricia M Simone; Kenneth G Castro Journal: Public Health Rep Date: 2006 Mar-Apr Impact factor: 2.792
Authors: Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran Journal: Emerg Infect Dis Date: 2014-05 Impact factor: 6.883
Authors: Ali Akbar Velayati; Parissa Farnia; Mohadese Mozafari; Donya Malekshahian; Shima Seif; Snaz Rahideh; Mehdi Mirsaeidi Journal: PLoS One Date: 2014-12-08 Impact factor: 3.240
Authors: Masashi Matsuyama; Andrew J Martins; Shamira Shallom; Olena Kamenyeva; Anuj Kashyap; Elizabeth P Sampaio; Juraj Kabat; Kenneth N Olivier; Adrian M Zelazny; John S Tsang; Steven M Holland Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: M V Aslam; K Owusu-Edusei; S M Marks; G R B Asay; R Miramontes; M Kolasa; C A Winston; P M Dietz Journal: Int J Tuberc Lung Dis Date: 2018-12-01 Impact factor: 2.373
Authors: Jose Cadena; Norys A Castro-Pena; Heta Javeri; Brian Hernandez; Joel Michalek; Ana Fuentes Arzola; Miloni Shroff; Chetan Jinadatha; Gustavo Valero; Jason Bowling; Jean Przykucki; Michele Adams; James Jorgensen; Jan E Patterson; Pranavi Sreeramoju Journal: Open Forum Infect Dis Date: 2017-09-16 Impact factor: 3.835